CRISPR Therapeutics CRSP Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.51M-90.6% | $37.31M-89.9% | $371.21M+30,885% | $1.2M-99.9% | ||
| $284.81M-8.2% | $310.24M-19.9% | $387.33M-16.1% | $461.65M+36.0% | ||
| $73.54M+0.8% | $72.98M-4.2% | $76.16M-25.7% | $102.46M+1.7% | ||
| $19.48M+1.1% | $19.26M-2.9% | $19.84M-17.9% | $24.17M+34.6% | ||
| $668.08M+32.6% | $503.88M-15.1% | $593.74M-12.0% | $674.36M+24.6% | ||
| $668.08M+32.6% | $503.88M-15.1% | $593.74M-12.0% | $674.36M+24.6% | ||
| -$664.57M-42.4% | -$466.57M— | —— | -$673.16M— | ||
| -18,933.6%-17,683pp | -1,250.4%— | —— | -56,190.4%— | ||
| $86.61M-16.6% | $103.9M+44.7% | $71.82M+217% | $22.66M+277% | ||
| -$577.97M-59.4% | -$362.67M— | —— | -$650.5M— | ||
| $3.63M+1.3% | $3.59M+24.2% | $2.89M+989% | -$325K— | ||
| -$581.6M-58.8% | -$366.25M— | —— | -$650.18M— | ||
| -16,569.8%-15,588pp | -981.5%— | —— | -54,271.7%— | ||
| -$6.50-49.4% | -$4.35— | —— | -$8.36— | ||
| -$6.50-49.4% | -$4.35— | —— | -$8.36— | ||
| 354.2M+5.3% | 336.3M+6.3% | 316.4M+1.9% | 310.4M-0.6% | ||
| 354.2M+5.3% | 336.3M+6.3% | 316.4M+1.9% | 310.4M+2.4% | ||
| $213.48M+76.9% | $120.67M-7.4% | $130.25M+18.1% | $110.25M+9.0% | ||
| -$578.62M-58.0% | -$366.33M— | —— | -$660.75M— | ||
| —— | -$27.28M-34.8% | -$20.25M— | —— | ||
| —— | —— | $200M+65,674% | -$305K-289% | ||
| —— | —— | $110K— | —— | ||
| -$3.34M+39.0% | -$5.47M+76.4% | -$23.22M— | —— | ||
| $94K+570% | -$20K-128% | $72K— | —— | ||
| $3.05M+5,860% | -$53K-100% | $17.49M— | —— | ||
| $86.61M-16.6% | $103.9M+44.7% | $71.82M+217% | $22.66M+277% | ||
| $914K-51.9% | $1.9M-79.9% | $9.47M-74.5% | $37.19M-54.5% | ||
| $3.51M-90.6% | $37.31M-89.9% | $371.21M+30,885% | $1.2M-99.9% | ||
| $72.5M-16.3% | $86.57M+6.8% | $81.03M-17.3% | $97.95M-4.3% | ||
| -$664.57M-42.4% | -$466.57M— | —— | -$673.16M— | ||
| -$645.09M-44.2% | -$447.31M— | —— | -$648.99M— | ||
| -$645.09M-44.2% | -$447.31M— | —— | -$648.99M— | ||
| -18,378.7%-17,180pp | -1,198.8%— | —— | -54,172.7%— | ||
| -$664.57M-42.4% | -$466.57M— | —— | -$673.16M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is CRISPR Therapeutics's revenue?
- CRISPR Therapeutics (CRSP) generated $4.1M in revenue over the trailing twelve months, down 89.1% year over year.
- Is CRISPR Therapeutics profitable?
- CRISPR Therapeutics is not currently profitable: it reported a net loss of $568.5M over the trailing twelve months, a -13856.5% net margin.
- What is CRISPR Therapeutics's earnings per share?
- CRISPR Therapeutics's diluted EPS over the trailing twelve months is $-6.20.
- Where does CRISPR Therapeutics's income statement data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
